Ovarian cancer is one of the leading causes of death in patients with gynecological
malignancy. Despite optimal cytoreductive surgery and platinum-based chemotherapy …

The biology of ovarian carcinoma differs from that of hematogenously metastasizing tumors
because ovarian cancer cells primarily disseminate within the peritoneal cavity and are only …

We conducted a pilot clinical trial testing a personalized vaccine generated by autologous
dendritic cells (DCs) pulsed with oxidized autologous whole-tumor cell lysate (OCDC) …

Standard therapy for platinum-resistant ovarian cancer (OC) is single-agent chemotherapy.
The most active single agents are pegylated liposomal doxorubicin, paclitaxel, and …

Background Angiogenesis plays a role in the biology of ovarian cancer. We examined the
effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women …

Purpose This randomized, multicenter, blinded, placebo-controlled phase III trial tested the
efficacy and safety of bevacizumab (BV) with gemcitabine and carboplatin (GC) compared …

Epithelial ovarian cancer is the most lethal of the gynecologic malignancies, largely due to
the advanced stage at diagnosis in most patients. Screening strategies using ultrasound and …

Objective Ovarian cancer is the deadliest gynecologic malignancy and the fifth leading
cause of death from cancer in women in the US Since overall survival remains poor, there is …

The dependency of the growth of tumors on blood vessels, once considered a doubtful
proposition, has become a major avenue of research and drug development. This review …

Several vascular endothelial growth factor (VEGF)-targeted agents, administered either as
single agents or in combination with chemotherapy, have been shown to benefit patients …